CN101698029A - Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis - Google Patents
Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis Download PDFInfo
- Publication number
- CN101698029A CN101698029A CN200910186459A CN200910186459A CN101698029A CN 101698029 A CN101698029 A CN 101698029A CN 200910186459 A CN200910186459 A CN 200910186459A CN 200910186459 A CN200910186459 A CN 200910186459A CN 101698029 A CN101698029 A CN 101698029A
- Authority
- CN
- China
- Prior art keywords
- lipide
- actives
- active substance
- application
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to application of a lipid active substance of a theaceous plant in treating hormone-dependent dermatitis. A treatment method is to prepare the lipid active substance into an acceptable dosage form, an intestinal administration or local administration mode is adopted, and the lipid active substance has the efficacies of clearing heat and releasing toxin, dispelling wind and eliminating dampness, nourishing yin and cooling blood; the lipid active substance is locally smeared at least twice every day in external use, and the smearing amount is determined according to the skin area and the skin absorption condition; and the lipid active substance has the functions of backing red, dispersing swelling and relieving ache and itch, is also favorable for wound surface epithelial cell formation, granulation tissue growth and wound surface healing, can be used for preparing a product for preventing and treating the hormone-dependent dermatitis, provides a brand-new treatment scheme with exact treatment effect for patients, and also can make full use of natural resources and improve the human health-care level and the quality of life.
Description
Technical field
The present invention relates to the application of lipide actives in the control steroid-dependent dermatitis from plant of theaceae.
Background technology
Because glucocorticoid has effects such as suppressing immunoreactive antiallergic, antiinflammatory, anti-hypertrophy, can alleviate hyperemia and edema after the external, reduce and ooze out and cellular infiltration, make the inflammatory reaction of the degree of pruritus and some skin lesion temporarily be alleviated and disappear.
The doctor holds inaccurate to the indication that external contains hormone product, or the excessive external of patient contains the struvite skin lesion that hormone product causes, this skin lesion has in various degree dependence to hormone, because this dependency forces patient's life-time service hormone and can not stop using, skin lesion is increased the weight of, the state of an illness is more serious, claims steroid-dependent dermatitis; Skin lesion is a feature with erubescence, pimple, atrophy, attenuation, telangiectasis, acne and the change of rosacea sample etc., and subjective symptoms is based on scorching hot, pruritus, pain, drying, desquamation and nervous sense.
The steroid-dependent dermatitis morbidity is ascendant trend year by year, and obstinate again refractory has become the focus that medical experts pay close attention to more.
Up to now, the pathogeny of steroid-dependent dermatitis is not clear and definite fully as yet yet, thinks at present and may cause atrophoderma relevant with 17-hydroxy-11-dehydrocorticosterone; Atrophoderma causes stratum corneum gets thinner again, the dermal papilla regression, and skin barrier is impaired; And then cause the excessive dehydration of skin, make the skin of normal or existing pathological changes produce inflammation.
At present, western modern medicine does not have specific short, mainly takes " the slow method (substitution method) of stopping ", successively decrease gradually intensity, the consumption of hormonal medicaments cooperate anti-inflammation, the Claritin treatment again, up to all removing hormonal medicaments, recover skin barrier function, eliminate partial skin lesion; The Therapeutic Principle who emphasizes primary disease is localised protection and pacifies, the more important thing is the self renewal effect of skin.Therefore adopt this scheme to recover slower, most of patients is this recovery from illness process of recovering slowly of difficult acceptance also.
Chinese medicine has shown good expection in the treatment to this disease, improve and cure aspect the symptoms such as flush, telangiectasis, pigment variation, state of an illness knock-on with the obvious advantage, for facial acne sample erythra, itch and symptom such as discomfort, close with the western modern medicine curative effect.
Theaceae belongs to Dilleniidae (Dilleniidae), Theales (Theales), about 30 belong to 750 kinds, the subtropical zone and the torrid zone in the Asia that mainly distributes, in state-owned 15 belong to 500 kinds, have very high economic worth; The Folium Camelliae sinensis that originates from Camellia sinensis (Camellia sinensis) is one of the world's four big beverages.Oil tea (C.oleifera) is the important woody edible oil materials seeds in low-relief terrain on the south the Chinese the Changjiang river.Camellia reticulata (C.reticulata) is one of world-renowned flowers; Flos Camelliae Japonicae (C.japonica) is common flower garden Guan Shu, and Camellia nitidissima Chi (C.chrysantha) is the first-grade state protection plant.
At the flower of different plant of theaceae, stem, leaf, branch, seed is in the root, there is the lipide actives that has the water insoluble of similar even identical biological activity and physicochemical property or be slightly soluble in water, can use the way of distillation, milling process, known methods such as extraction obtain, the most common form with liquid exists, by further purification, modification can obtain solids.
At present, the research of this type of material is hankered after purifying and illustrated the wherein physicochemical property and the biological activity of a certain material, as catechin-derived thing, fatty oil, saponin component, for the application of such material, also be in the initial stage, mainly concentrate on the one matter antioxidation, fat-reducing, antitumor, blood lipid regulation, blood pressure, blood glucose, the application of aspects such as burn and scald.Reduced the range of application of plant of theaceae lipide actives, the compatibility of such material that weakened uses.
Summary of the invention
Purpose of the present invention is exactly according to deficiency pointed in the above-mentioned background technology, defers to the traditional Chinese medical science " monarch " theory, and a kind of application of lipide actives in the control steroid-dependent dermatitis from plant of theaceae is provided.
Lipide actives of the present invention derives from the flower of plant of theaceae, rhizome, leaf, branch, seeds etc. contain volatile aromatic substance, the fatty acid ester of fixedness, fatsoluble vitamin and derivant thereof (as dimension A, dimension E, dimension K etc.), catechin-derived thing, saponin, Squalenes (alkane) etc. have heat-clearing and toxic substances removing, expelling wind and removing dampness, the effect of YIN nourishing removing heat from blood has been brought into play unexpected effect in the treatment of steroid-dependent dermatitis.
Therapeutic Method is that lipide actives is made acceptable forms, and partial smearing is smeared secondary every day at least in patient's diseased region, and applying amount is determined according to skin area size and skin absorbs situation, should be comprised lipide actives 0.01mL of the present invention (mg)/cm
2More than; Look the state of an illness, oral administration comprises lipide actives of the present invention.
Behind the externally used coating lipide actives of the present invention, form one deck protection barrier, the pessimal stimulation that alleviates outer bound pair wound surface with the wound tissue surface combination; both had move back red, the detumescence, relieve the pain; itching-relieving action helps the effect of the formation of wound surface epithelial cell, granulation tissue growth and wound healing again.
Lipide actives of the present invention can make the patient break away from hormone, has the effect of treatment steroid-dependent dermatitis, is used to prepare the product of prevention and treatment steroid-dependent dermatitis, for the patient provides a kind of brand-new, and the therapeutic scheme of determined curative effect; Also can make full use of the natural resources, improve human health care's level and quality of life.
Specific embodiment
Now in conjunction with the embodiments the present invention is done a description.
Embodiment 1: lipide actives is treated 30 routine facial steroid-dependent dermatitis clinical observations
One data and method
1 inclusion criteria
(1) the above fixed position external hormone product history of two weeks is arranged;
(2) stop using and to contain behind the hormone product original disease or skin lesion recurrence in 2～10 days or increase the weight of; Hormone occurs and rely on phenomenon (be to bounce after the drug withdrawal, original disease or skin lesion recur or increase the weight of, and reuse the back sx);
(3) typical skin lesion: with erythema, pimple, drying and desquamation is the multiformity skin lesion of basic infringement, is difficult to other dermatosiss exponent;
(4) subjective symptom: conscious local pruritus, burn sample pain, tight bloated sense or dry uncomfortable, above-mentioned symptom is met heat and is increased the weight of, meets cold alleviating.
Have (1), (2) and (3), (4) respectively see one or more person.
2 get rid of case
(1) age is person below 12 years old or more than 60 years old;
(2) gestation or women breast-feeding their children;
(3) merge to have the inclination, cerebrovascular and serious primary disease person such as liver, kidney and hemopoietic system and psychotic;
(4) use antihistamine drug and immunomodulator drug withdrawal less than 1 all persons.
3 physical data
30 routine out-patients, male 5 examples, women 25 examples; Age between 20～50 years old, external hormone 2 months～3 years, all through desensitization treatment repeatedly, effect is not good enough.
4 Therapeutic Method
The self-control lipide actives is made the pale yellow oily liquid body, intends being higher than the company standard of Vegetable oil lipoprotein national standard certainly, and the accelerated stability test result shows and can preserve 3 years in shady and cool dry place.Embedding is stand-by in hermetic container; During treatment, dip in cotton swab and to get outer putting on the skin, 3～4 times/d, observe curative effect weekly 1 time, 1 month is 1 course of treatment.
5 curative effect determinate standards
(1) skin lesion degree scoring
4 objective indicators: flushing, telangiectasis, pigment change and acneform eruptions
1 subjective index: sense of discomfort
The integration standard is: 0 is divided into nothing, and 1 is divided into slightly, and 2 are divided into moderate, and 3 are divided into severe; Full marks are 15 minutes.
(2) clinical efficacy is judged
Calculate patient's integrated value before the treatment and after the treatment respectively, and calculate the integration slip according to formula:
Integration * 100% before integration slip=(integration before the treatment-treatment back integration)/treatment.
By recovery from illness, produce effects, effective, invalid 4 standards, total effective rate adds produce effects with recovery from illness and calculates.After 1 week of drug withdrawal, obvious flushing, pimple, pruritus etc. occur and be recurrence.
Recovery from illness: treat back integration≤1.
Produce effects: integration slip 〉=70%.
Effectively: the integration slip is 40%～69%.
Invalid: the integration minimizing is lower than 40%.
Two results
1, after course of treatment, 21 examples of fully recovering (70%), produce effects 6 examples (20%), effective 3 examples (10%), total effective rate 90%.
2, after course of treatment, symptom integral changes before and after the treatment, sees the following form.
Symptom integral variation before and after the table treatment (x ± s)
| Treat the same day | Treated for 1 week | Treated for 2 weeks | Treated for 3 weeks | Treated for 4 weeks |
| ??15.34±??3.89 | ??12.26±??2.23 | ??8.03±??3.62 | ??4.47±1.54 | ??1.65±??0.22 |
3, successive treatment
The treatment of first course of treatment effectively reaches total 9 examples of produce effects, the treatment that enters second course of treatment after finishing.8 example recoveries from illness, after the treatment of 1 example through the 3rd course of treatment, recovery from illness.
4, recurrence situation after the drug withdrawal
Treat and finish in back 6 months the recovery from illness patient to be followed up a case by regular visits to,, all do not have recurrence except that there being 2 examples to lose the visit.
5 untoward reaction
9 examples (30%) local rubescent, pruritus occurs and increase the weight of when using first, continue to use, and alleviate after 1 week, do not stop treatment.
Embodiment 2: lipide actives is treated 50 routine facial steroid-dependent dermatitis clinical observations
One data and method
1 inclusion criteria is with embodiment 1
2 get rid of case with embodiment 1
3 physical data
Totally 100 routine patients, wherein male 22 examples, women 78 examples; 21～50 years old age; Once external betamethasone, clobetasone etc., average 7.3 months (1 month～12 years).
100 routine patients are divided into treatment group [50 examples, age (32.2 ± 5.99) year] and matched group [50 examples, age (31.82 ± 7.52) year old] at random.Treatment group and matched group do not have significant difference at aspects such as age, sex, the course of disease and symptom score, have comparability.
4 Therapeutic Method
The treatment group: the self-control lipide actives, make the pale yellow oily liquid body, company standard, accelerated stability test result show and can preserve 3 years in shady and cool dry place.Embedding is stand-by in hermetic container; During treatment, dip in cotton swab and to get outer putting on the skin, 3～4 times/d, observe curative effect weekly 1 time, 1 month is 1 course of treatment.
Matched group: external 5% Butyl Flufenamate Ointment, observe curative effect weekly 1 time every day 3 times, 1 month is 1 course of treatment.
5 curative effect determinate standards are with embodiment 1
6 statistical methods
Date processing adopts one factor analysis of variance and x2 check, α=0.05.
Two results
Treatment group and matched group are finished the whole course of treatment respectively on request.Symptom score sees Table 1; Therapeutic effect sees Table 2; Two groups of effective percentage are through x 2 checks, and difference has statistical significance.
Table 1 treatment group and matched group symptom score are relatively
Annotate * P＜0.01
Table 2 liang group curative effect relatively
| Group | The example number | Recovery from illness (routine number, %) | Produce effects (routine number, %) | Effectively (routine number, %) | Invalid (routine number, %) | Total effective rate (%) |
| The treatment group | ??50 | ??33??64％ | ??10??20％ | ??8???16％ | ??0??0 | ??84％??* |
| Matched group | ??50 | ??25??50％ | ??7???14％ | ??10??20％ | ??8??16％ | ??64％ |
Annotate: * P＜0.01
Although described some relevant embodiment of the present invention here; those skilled in the art can recognize; can carry out various changes and improvements to the present invention but do not deviate from essence of the present invention, we are intended to statement, and these changes and improvements all fall within the scope of protection of present invention.
Claims (5)
1. from the application in the treatment steroid-dependent dermatitis of the lipide actives of plant of theaceae, it is characterized in that: described lipide actives derives from the flower of plant of theaceae, stem, leaf, branch, seed, the position of root, described dermatosis is to hormone or contain the hormones product and have certain dependency.
2. according to claim 1 from the application in the treatment steroid-dependent dermatitis of the lipide actives of plant of theaceae, it is characterized in that: described lipide actives is to adopt to extract extraction mode, a kind of mixture that contains volatile material and involatile substance that obtains.
3. according to claim 1 from the application of lipide actives in the treatment steroid-dependent dermatitis of plant of theaceae, it is characterized in that: described lipide actives is made the oral application dosage form use, be preferably: solution, capsule, tablet, granule, drop.
4. according to claim 1 from the application of lipide actives in the treatment steroid-dependent dermatitis of plant of theaceae, it is characterized in that: described lipide actives is made the topical application dosage form, be preferably: liniment, emulsion, gel, cream, liniment, suppository.
5. according to claim 1 from the application in the treatment steroid-dependent dermatitis of the lipide actives of plant of theaceae, it is characterized in that: the product that will comprise described lipide actives is applied in patient's diseased region, at least smear secondary every day, applying amount should be equivalent to lipide actives 0.01mL (mg)/cm
2And more than.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910186459A CN101698029A (en) | 2009-11-09 | 2009-11-09 | Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910186459A CN101698029A (en) | 2009-11-09 | 2009-11-09 | Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101698029A true CN101698029A (en) | 2010-04-28 |
Family
ID=42146493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910186459A Pending CN101698029A (en) | 2009-11-09 | 2009-11-09 | Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101698029A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106983703A (en) * | 2017-05-24 | 2017-07-28 | 广州珈源日化用品有限公司 | A kind of cosmetic composition for repairing hormone injured skin and its preparation method and application |
-
2009
- 2009-11-09 CN CN200910186459A patent/CN101698029A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106983703A (en) * | 2017-05-24 | 2017-07-28 | 广州珈源日化用品有限公司 | A kind of cosmetic composition for repairing hormone injured skin and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091203B (en) | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof | |
| CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
| CN102949647A (en) | Medical composition for killing bacteria and relieving itching and preparation method of same | |
| CN103877247B (en) | Medicine being used for the treatment of decubital ulcer and preparation method thereof | |
| CN102114217B (en) | Traditional Chinese medicine fumigant for treating tinea capitis | |
| CN102872241A (en) | Traditional Chinese medicinal composition for treating inflammatory dermatosis and preparation thereof | |
| CN102716304B (en) | Traditional Chinese medicine preparation for treating dermatosis and preparation method thereof | |
| CN105213256A (en) | A kind of Shu Min dispels red toner/smoothing toner and preparation method thereof | |
| CN105497537A (en) | Medicine composition with skin whitening and tendering functions and preparing method thereof | |
| CN104721489A (en) | Chinese patent medicine for treating Parkinson disease and preparation method thereof | |
| CN101698029A (en) | Application of lipid active substance of theaceous plant in treating hormone-dependent dermatitis | |
| CN101703667B (en) | Brown red medicament for treating traumatic injuries and preparation method thereof | |
| CN104147198A (en) | Traditional Chinese medicine compound for treating papular acne and preparation thereof | |
| CN107875256B (en) | Zhuang-medicine acupoint application plaster for treating insomnia and manufacturing method thereof | |
| CN101904998A (en) | Special medicament for treating dermatophytosis and preparation method thereof | |
| CN104689240A (en) | Medicine for treating Qi-stagnation and blood stasis type chloasma and preparation method thereof | |
| CN104474405A (en) | Traditional Chinese medicine composition for treating chloasma | |
| CN102949567A (en) | Medicinal capsule for removing chloasma and preparation method thereof | |
| CN103599272B (en) | Chinese herbal lotion for the treatment of gynecological inflammation and preparation method thereof | |
| CN116570700B (en) | Traditional Chinese medicine preparation with antibacterial, anti-inflammatory and acne removing effects and application thereof | |
| CN101926859B (en) | Chinese medicinal composition | |
| CN104645244A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| CN104606542A (en) | Traditional Chinese medicine composition containing maca as well as preparation method and application of composition | |
| CN105106590A (en) | Medicine for treating allergic rhinitis | |
| CN114796312A (en) | Anti-allergic and anti-inflammatory traditional Chinese medicine preparation for treating infantile eczema and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100428 |